



Biotech Daily

Monday July 26, 2010

Daily news on ASX-listed biotechnology companies

*** BPH'S DR ROBIN SCAIFE WINS \$75k MELANOMA DRUG GRANT**

BPH CORPORATE

BPH says its principal researcher Dr Robin Scaife has been awarded \$75,000 from the Scott Kirkbride Melanoma Research Centre.

BPH said the funds would assist a melanoma drug discovery program at the Western Australian Institute for Medical Research.

The company said the Scott Kirkbride Melanoma Research Centre supported research for improved diagnosis and treatment of melanomas and was established in 2005 in memory of Perth golfer, Scott Kirkbride, who died from melanoma in 2004 at the age of 27 years. BPH said that although melanomas had a reputation for being particularly refractory to therapeutic intervention, some types of melanoma had been shown to respond well to a new class of customized cancer drugs.

The company said that Dr Scaife and his collaborators at the Western Australian Institute for Medical Research and the University of Western Australia, would use the high-content imaging and analysis platform at Molecular Discovery Systems to screen an arsenal of new drug-like molecules for inhibitors of melanoma cell survival and proliferation.

BPH owns 20 percent of Molecular Discovery Systems following last year's in specie share return.

BPH fell 1.5 cents or 13.0 percent to 10 cents with 5.2 million shares traded.